SunTrust Robinson Humphrey upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Hold to Buy with a price target of $45.00.Analyst Ed Nash ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE